New York, NY, United States of America

Michael Trzoss

This inventor holds 1 USPTO granted patent. Top assignee: Schrodinger, LLC. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Trzoss. Retrieved from https://idiyas.com/inventor/michael-trzoss-64u6wfhx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Trzoss: Inventor in Cancer and Inflammatory Disorder Research.

Introduction

Michael Trzoss is an inventor associated with Schrodinger, LLC, in New York, New York. His patent work concerns compounds investigated for potential use in treating cancer, autoimmune disorders, and inflammatory conditions.

Latest Patents

The supplied information lists one patent associated with Trzoss: “Tricyclic Compounds Useful in the Treatment of Cancer, Autoimmune and Inflammatory Disorders.” The patent describes tricyclic compounds directed toward these therapeutic areas. The provided data identifies 1 patent and does not specify its filing or grant date.

Career Highlights

Trzoss is associated with Schrodinger, LLC, a company whose work includes computational approaches to drug discovery. His listed patent reflects an inventive contribution focused on therapeutic compounds.

Collaborations

The supplied information names Shulu Feng and Morgan Lawrenz as coworkers. Their inclusion indicates professional connections, but the available details do not establish their specific roles in the patent.

Conclusion

Michael Trzoss’s listed patent connects his inventive work at Schrodinger, LLC, with research into compounds for cancer, autoimmune disorders, and inflammatory conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…